Entering text into the input field will update the search result below

Vanda Pharmaceuticals reports Q1 results

May 03, 2023 4:46 PM ETVanda Pharmaceuticals Inc. (VNDA)By: Anuron Mitra, SA News Editor
  • Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q1 GAAP EPS of $0.06.
  • Revenue of $62.5M (+3.8% Y/Y).
  • Given uncertainties surrounding the U.S. market for HETLIOZ for the treatment of Non-24 as a result of the ongoing HETLIOZ patent litigation and the at-risk launch of a generic version of HETLIOZ, VNDA is unable to provide 2023 financial guidance at this time.
  • HETLIOZ net product sales will likely decline in future periods, potentially significantly, related to the at-risk launch of a generic version of HETLIOZ in the U.S.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.